[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136(5): E359-386. [2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5. [3] Safa AR.Resistance to cell death and Its modulation in cancer stem cells[J].Crit Rev Oncog, 2016, 21(3-4): 203-219. [4] St John MA, Abemayor E, Wong DT.Recent new approaches to the treatment of head and neck cancer[J]. Anticancer Drugs, 2006, 17(4): 365-375. [5] Javazon EH, Beggs KJ, Flake AW.Mesenchymal stem cells: paradoxes of passaging[J]. Exp Hematol, 2004, 32(5): 414-425. [6] 郑天亮, 赵松, 郭海周, 等. 骨髓间充质干细胞促进肺癌转移的机制[J].中国组织工程研究, 2016, 20(19): 2783-2788. [7] 文政伟, 余洁梅, 晏洁影, 等. 骨髓间充质干细胞对肝癌细胞MHCC97-H和MHCC97-L侵袭能力和增殖能力的影响[J].临床和实验医学杂志, 2016, 15(2): 110-112. [8] Kéramidas M, de Fraipont F, Karageorgis A, et al. The dual effect of mesenchymal stem cells on tumour growth and tumour angiogenesis[J]. Stem Cell Res Ther, 2013, 4(2): 41. [9] Wang Y, Luther K.Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway[J]. Prog Mol Biol Transl Sci, 2012, 111: 265-284. [10] Wang K, Zhao X, Kuang C, et al.Overexpression of SDF-1αenhanced migration and engraftment of cardiac stem cells and reduced infarcted size via CXCR4/PI3K pathway[J]. PLoS One, 2012, 7(9): e43922. [11] Hamada H,Kobune M, Nakamura K, et al.Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy[J].Cancer Sci, 2005, 96(3): 149-156. [12] Mishra PJ, Humeniuk R, Medina DJ, et al.Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells[J]. Cancer Res, 2008, 68(11): 4331-4339. [13] Xu WT, Bian ZY, Fan QM, et al.Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis[J]. Cancer Lett, 2009, 281(1): 32-41. [14] Ahn JO, Coh YR, Lee HW, et al.Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo [J]. Anticancer Res, 2015, 35(1): 159-168. [15] Choumerianou DM, Martimianaki G, Stiakaki E, et al.Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults[J]. Cytotherapy, 2010, 12(7): 881-887. [16] Acloque H, Adams MS, Fishwick K, et al.Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease[J]. J Clin Invest, 2009, 119(6): 1438-1449. [17] 张平平, 徐秀英, 高振南. 低糖基化E-cadherins对舌鳞癌细胞增殖和侵袭的影响[J]. 上海口腔医学, 2014, 23(1): 1-6. [18] Zeisberg M, Neilson EG.Biomarkers for epithelial-mes-enchymal transitions[J]. J Clin Invest, 2009, 119(6): 1429-1437. [19] Kalluri R, Weinberg RA.The basics of epithelial-mesenchy-mal transition[J]. J Clin Invest, 2009, 119(6): 1420-1428. [20] Thiery JP, Lim CT.Tumor dissemination: an EMT affair[J]. Cancer Cell, 2013, 23(3): 272-273. [21] Rhim AD, Mirek ET, Aiello NM, et al.EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148(1-2): 349-361. [22] Kudo-Saito C, Shirako H, Takeuchi T, et al.Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells[J]. Cancer Cell, 2009, 15(3): 195-206. [23] Yang J, Weinberg RA.Epithelial-mesenchymal transition:at the crossroads of development and tumor metastasis[J]. Dev Cell, 2008, 14(6): 818-829. [24] Belleguic C, Corbel M, Gerxnain N, et al.Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients[J]. Clin Exp Allergy, 2002, 32(2): 217-223. [25] Radisky DC, Levy DD, LittIepage LE, et al. Raclb and reactive oxygen species mediate MMP-3-induced EMT and genomic instability[J]. Nature, 2005, 436(7047): 123-127. [26] Joseph MJ, Dangi-Garimella S, Shields MA, et al.Slug is a downstream mediator of transforming growth factor-betal-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells[J]. J Cell Biochem, 2009, 108(3): 726-736. [27] Tutton MG, George ML, Eccles SA, et al.Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients[J]. Int J Cancer, 2003, 107(4): 541-550. [28] Shrestha B,Bajracharya D.May high MMP-2 and TIMP-2 expressions increase or decrease the aggressivity of oral cancer?[J]. Pathol Oncol Res, 2016, 23(1): 197-206. |